Most common cancer
in women worldwide
New tool to improve
standard of care
Breast cancer is the most common cancer for women both in the U.S. and worldwide. Intensive research has been and continues to be conducted in this area, and to date, it has been generally accepted that the most effective means of control lies in early detection. Each breast cancer diagnostic tools has its advantages and limitations, but for the most part, there is room for improvements. It is time to optimize the screening, diagnosis, and treatment of breast cancer. If you are looking for fresh news, innovative approaches, and a health solution that scale– you have come to the right place.
Enhancing the thoroughness and improving how well and how fast tissue abnormalities are detected can significantly improve the effectiveness of medicine overall. We believe in a “patient-centric technology for all women”, one that is safe, reliable, accessible, and scalable. I.e. a technology that has the exponential potential to reach women regardless of geographic location and/or socio-economic status.
Come one, come all. Employers, Brokers, Benefit Directors, Health Plan Providers, TPA’s and anyone who cares about women’s health are invited. Features presenters from expert medical oncology specialist and a seasoned healthcare Sales and Marketing VP. This interactive and educational meeting will discuss a novel approach to breast cancer screening and will also engage in a peer-exchange discussion and address audience questions."
Jaime is an accomplished international executive with over 30 years of experience in the Life Sciences Industry. Throughout his career, Jaime has held senior management positions in global companies in the pharmaceutical, medical devices, and biotech fields.
His successful sales and marketing experience include leading roles in S&P 500 companies such as Johnson & Johnson and Abbott Laboratories, launching and leading initiatives in the U.S., Central America, South America, and Europe.
Jaime earned a BS in Business from Louisiana State University and completed an executive MBA at Northwestern Kellogg School of Management.
Dr. Montero is a Physician in the Department of Solid Tumor Oncology at Cleveland Clinic, specializing in breast cancer for the last 13 years.
Throughout his medial career, he has led process improvements in oncology to develop effective and efficient treatment strategies in breast cancer achieving better clinical outcomes and a superior quality of care for patients.
He has been the principal investigator in over 30 clinical trials, he has co-authored over 50 peer reviewed publications and several studies examining the cost-effectiveness of targeted therapies currently utilized for the treatment of metastatic breast cancer. He has also served on data safety and monitoring committees in two academic institutions,and have prior experience serving as the head of a Data Safety Monitoring Committee.
Dr. Montero earned his Medical Degree from the University of Texas Medical Branch at Galveston. He completed his fellowship training in hematology/oncology at the University of Texas M.D. Anderson Cancer Center.